Symptoms at presentation for patients admitted to hospital with Covid-19: results from the ISARIC prospective multinational observational study

Authors

ISARIC Clinical Characterisation Group *

* Members listed at end of manuscript

Keywords

Covid-19, SARS-CoV-2, symptoms, diagnosis, case definition

Running title

Covid-19 symptoms at hospital admission

Correspondence to

Dr Mark G Pritchard
Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
mark.pritchard@ndm.ox.ac.uk

Alternate corresponding author

Professor Piero L Olliaro
Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Summary

Typical symptoms of fever, cough and shortness of breath are less common in people admitted to hospital with Covid-19 toward extremities of age. Published case definitions appear less sensitive toward extremes of age, and atypical symptoms need to be recognised.
Abstract

Background

Symptom recognition is necessary to identify people with possible Covid-19. Clinical case definitions vary in type and number of symptoms included. No large studies have investigated how these perform for hospitalized patients of different ages and sex.

Methods

We used international prospective observational data from patients admitted to hospital with laboratory-confirmed Covid-19. We investigated how symptoms varied by age and sex. We performed logistic regression to assess the relationship of age and sex with the most prevalent symptoms in our dataset and with published case definitions, allowing for clustering by country as a random intercept.

Results

60,161 patients from 43 countries were included, with median age 70 years (interquartile range 55–82). Fever (68%), cough (68%) and shortness of breath (63%) were the most prevalent symptoms. Their prevalence was greater among patients aged 30–60 years (respectively 79%, 78%, 66%), and lower in children (≤18 years: 68%, 47%, 22%) and older adults (≥70 years: 61%, 62%, 61%). The most sensitive case definition assessed was one or more of cough, shortness of breath, fever, muscle pains or sore throat, met by 92% of the whole cohort. Confusion was the most prevalent symptom for patients whose symptoms did not meet any of the assessed case definitions. Regression models showed significant differences in symptoms with age, and considerable heterogeneity between countries.

Conclusions

Older adults and children admitted to hospital with Covid-19 are less likely to present with typical symptoms of cough, fever and shortness of breath. Vigilance for atypical symptoms towards extremities of age increases sensitivity of identifying Covid-19.
For emerging infectious diseases, knowledge of symptoms is vital to identify people with possible infection and follow-up actions [1]. Details of exposures, symptoms, signs and investigations are combined into case definitions to classify suspected, probable and confirmed cases. These can be used for disease surveillance, to guide public health actions, and case management. In settings without microbiological testing, these criteria may be used to reach a clinical diagnosis; in settings where testing is available they may be used to guide testing strategies [2].

Covid-19 emerged in December 2019, caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) [3, 4]. The most frequently reported symptoms were fever, cough and shortness of breath, together with a range of less frequent symptoms [4-8]. Altered sense of taste and smell have been found to be strongly associated with Covid-19 [2, 9, 10]. The World Health Organization (WHO) surveillance case definition (used by the European and African Centres for Disease Control) for people who have been in a location with community transmission of Covid-19 requires fever and at least one sign or symptom of respiratory disease, such as cough or shortness of breath [11]. The Centers for Disease Control and Prevention in the United States provides a non-exhaustive list of respiratory, enteric and constitutional symptoms: fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, and diarrhoea [12]. Public Health England’s definition of a possible Covid-19 case in the community is any one of new continuous cough, high temperature, or change to sense of taste or smell [13]. For inpatients, their definition is evidence of pneumonia, acute respiratory distress syndrome, or one of two clusters of symptoms: fever with at least one of cough, hoarseness, nasal discharge or congestion, shortness of breath, sore throat, wheezing or sneezing; or any change in sense of taste of smell [13].

Despite Covid-19’s status as a pandemic, large reports of clinical characteristics have so far been limited to cohorts from China, Europe and the United States [14]. There have also been no reports of differences in symptoms according to age or sex from large cohorts. Our primary
objective was to investigate how symptoms of patients admitted to hospital with confirmed Covid-19 vary by age and sex. Secondarily we aimed to investigate how sensitivity of clinical case definitions varied among these populations, and to explore heterogeneity between countries.

Methods

Study design and setting

This analysis used international observational data of clinical features of patients admitted to hospital with Covid-19 between 30 January and 3 August 2020. The International Severe Acute Respiratory and emerging Infection Consortium (ISARIC)/WHO Clinical Characterisation Protocol for Severe Emerging Infections is a standardized protocol for investigation of severe acute infections by pathogens of public health interest [15]. The ISARIC case report forms [16] allow standardized data collection from the start of an outbreak and rapid dissemination of clinical information [4, 17-21]. Different tiers of data collection exist to allow sites to collect data to the highest possible standards while recognising varying levels of resource for data collection during epidemics. Details of symptoms at admission were included on the case report forms for all tiers. Data were collected via electronic ‘Core’ and ‘Rapid’ forms by the ISARIC Clinical Characterisation Group, and through aligned forms by ISARIC-4C Coronavirus Clinical Characterisation Consortium in the United Kingdom [22] and the COVID-19 Critical Care Consortium [23]. Investigators from 41 countries are using Research electronic Data Capture (REDCap, version 8.11.11, Vanderbilt University, Nashville, Tenn.) to contribute their data to a central database hosted by the University of Oxford. Additional data were submitted by investigators from Malaysia, Russia [24] and Spain, who were not using the University of Oxford REDCap instance. All investigators retained full rights to their data.

Study population

Patients of any age admitted to hospital with suspected or confirmed Covid-19 were eligible for recruitment. Some versions of the case report form included specific criteria such as fever and cough, but investigators were able to include patients with a clinical suspicion of Covid-19 even if...
these criteria were not met. This analysis was limited to patients who were admitted to hospital with symptomatic laboratory-confirmed Covid-19, according to sites' local diagnostic methods. We excluded asymptomatic patients who had been admitted to hospital for isolation and patients admitted for other conditions who subsequently developed Covid-19 symptoms.

Variables and measurement

Variables used in this analysis were age, sex at birth, symptoms, date of symptoms onset, SARS-CoV-2 confirmation, and country of recruitment. To allow proportions to be calculated with a reliable denominator, only symptoms prespecified on the case report forms [16, 22, 23] were included in this analysis. The list of symptoms collected is presented with the results.

Ethical considerations

This observational study required no change to clinical management and permitted enrolment in other research. The study was approved by the World Health Organization Ethics Review Committee (RPC571 and RPC572). Local ethics approval was obtained for each participating country and site according to local requirements.

Statistical methods

Data were converted to Study Data Tabulation Model (version 1.7, Clinical Data Interchange Standards Consortium, Austin, Tex.) to allow inclusion of data submitted not using the ISARIC case report forms. We excluded patients with all symptoms recorded as missing or unknown, and those with missing age, sex, country or onset date.

Continuous variables were expressed as median with interquartile range, and categorical variables as counts with percentages. We tested for differences between female and male patients using Wilcoxon rank-sum tests for continuous variables and chi-square tests for categorical variables. We grouped patients into ten-year age bands (with a single group for age ≥90 years). We plotted the most frequently reported symptoms by age group, presenting missing data as a third category.
We collated symptoms according to four sets of clinical criteria, based on published case definitions [11-13]:

1. Fever plus at least one of cough or shortness of breath;
2. Fever plus at least one of cough, nasal discharge, shortness of breath, sore throat, or wheeze;
3. Either cough or fever;
4. One or more of cough, shortness of breath, fever, muscle pains, or sore throat.

(Altered senses of smell and taste were not included in these classifications as they were not included on all versions of the case report forms so had high levels of missingness.) Patients with missing details of any symptoms included in these criteria were omitted from the composite groups.

We plotted proportions of patients meeting each set of criteria by ten-year age group, with 95% confidence intervals (CI) calculated using the Clopper–Pearson method.

We used logistic regression to identify associations of age and sex with the twelve most prevalent symptoms. Age group and sex were included as fixed effects, with country as a random intercept. To display heterogeneity between countries on the same scale as the fixed effects, we calculated median odds ratios (MOR) [25]. This quantifies variation between countries by comparing odds of an outcome between randomly chosen persons in different clusters who share the same covariates [25]. MORs are defined as a comparison of the group with greater propensity to the group with lower propensity, so lie in the range 1 to infinity [25]. We plotted the MOR to show the magnitude of the effect of heterogeneity and allow comparison with the fixed effects in our data.

79% of patients were recruited in a single country. As a sensitivity analysis, we repeated the analysis excluding patients from this country to see if results substantially changed. Finally, we plotted age-stratified symptom frequencies for each country with at least 250 patients.

No minimum sample size was calculated. All significance tests were two-tailed. Analyses were performed using R (version 3.6.2, R Foundation for Statistical Computing, Vienna, Austria) with packages including binom, Epi, ggplot2, lme4, sjstats, tableone, and tidyverse.
Results

Data were available for 99,623 patients. We excluded 24,336 who did not have documented SARS-CoV-2 confirmation, 2,583 with missing data, and 5,828 who developed Covid-19 after admission to hospital. 6,715 (9.6%) were admitted to hospital with a diagnosis of asymptomatic Covid-19. The greatest proportion of asymptomatic patients was in the age-band 10–20 years (46%, Supplementary Figure 1). The greatest proportion of asymptomatic patients was in Malaysia (49%), where hospitalization was compulsory throughout the data collection period for people with Covid-19. After excluding asymptomatic patients, 60,161 patients remained in the dataset (Figure 1). Included patients were recruited from 394 sites in 43 countries (Supplementary Table 1). 47,332 (79%) patients were included from the United Kingdom. The median age of included patients was 70 years (interquartile range [IQR] 54–82; Table 1). 930 (1.5%) were 18 years or younger. Of those older than 18 years, the median age was 70 years (IQR 55–82). The age distribution of patients varied among countries, between a median of 10 years in Poland, where a large proportion of included patients were children, and 73 years in the United Kingdom (Supplementary Figure 2). 34,674 (58%) patients were male. The most frequently reported symptoms were fever, cough and shortness of breath (Table 2). Fever, cough and shortness of breath were each significantly more prevalent in male patients, whereas less typical symptoms such as confusion, nausea and vomiting, diarrhoea, chest pain, headache and abdominal pain were more prevalent in female patients. The greatest sex-related difference was for nausea and vomiting, reported by 20% of female patients but only 14% of male patients. For most symptoms, the greatest prevalence was reported in adults aged between 30 and 60 years, decreasing toward extremities of age (Figure 2). Frequency of fatigue and confusion increased with age. Large numbers of patients had missing data for anorexia, severe dehydration, altered sense of taste and smell, and inability to walk as these were not included on all case report forms. Excluding these symptoms, few patients had missing data for the most prevalent symptoms. Data on symptoms included in the composite criteria were missing for 314 patients. The
clinical criteria were calculated for the remaining 59,847 participants. Each set of criteria was met by a greater proportion of patients aged 30 to 60 years than toward either extreme of age (Figure 3). The criteria of fever plus at least one of cough or shortness of breath was met by 35,394 (59%) patients, but only 37% of those aged 18 years and under, and 51% of those aged 70 years or over. The most sensitive criteria were one or more of cough, shortness of breath, fever, muscle pains, or sore throat, met by 55,198 (92%) participants. These criteria were met by 89% aged 18 years and under, and 89% of those aged 70 years or over. Each set of criteria were met by a greater proportion of male than female patients (Table 2).

For the 46,491 patients whose symptoms did not meet any of the assessed case definitions, the most frequent symptom was confusion (49%; Table 3). This rose with age to 67% of those aged 90 years or older. Nausea and vomiting, and abdominal pain were the most common symptoms for people less than 70 years old who did not meet any of the case definitions.

In the logistic regression models (Figure 4), similar associations between age and symptoms were seen after adjustment for sex and relationship of onset to admission date as in the unadjusted bar charts. Confusion increased with age. Nausea and vomiting, headache, abdominal pain, and sore throat were each more frequent in younger age groups, decreasing with age. The 95% CI for sex excluded one for most symptoms, but the point estimate was close to one for most. In these analyses, male patients had greater odds of fever, cough and shortness of breath, and lower odds of gastrointestinal symptoms of nausea and vomiting, diarrhoea, abdominal pain, chest pain, headache and sore throat. The median odds ratio for heterogeneity between countries was greater than the relationship with sex in all symptoms. It was of similar magnitude to the relationship with age for most symptoms. For each symptom, heterogeneity between countries was of a similar magnitude to the effect of age, and a greater magnitude than sex.

When we repeated the analysis excluding patients from the United Kingdom, the patterns of symptoms were similar to the main analysis (Supplementary Figure 3). The peak prevalence of fever, cough and shortness of breath was in 70- to 80-year-olds, and fatigue increased with age. This
resulted in a change to the calculated sensitivity of the clinical case definitions. Below the age of 50 years, each was less sensitive in the analysis excluding the United Kingdom than in the analysis including it; above the age of 70 years each was more sensitive (grey lines in Figure 3). Within countries, the baseline prevalence of each symptom varied but patterns within countries were broadly similar to the overall results (Supplementary figures 4–15).

Discussion

In this large, multinational cohort, we found that symptoms for people admitted to hospital with Covid-19 varied by age and sex. Typical symptoms of fever, cough and shortness of breath were each more prevalent between the ages of 30 and 60 years. Commonly used clinical case definitions identified greater proportions of patients between the ages of 30 and 60 years, and fewer in childhood and older age.

This is the first large assessment of Covid-19 symptoms by age. The presence of atypical symptoms in older adults has been recognised [26] but not evaluated in a large international cohort. Liu and colleagues [27] found similar distributions of symptoms between older and younger patients with Covid-19, but their older cohort had a median age of 68 years, which is younger than the median age of our total cohort. The finding of atypical presentations among older patients with Covid-19 correlates with similar findings of atypical presentations for pneumonia, bacteraemia and coronary artery disease [28, 29]. Lower prevalence of symptoms in children and young people has been recognised [30, 31], but no large international cohorts collecting data systematically from both adults and children been reported. Separate analyses on the ISARIC-4C data have identified clustering of symptoms in children [32] and adults [33]. In each, fever, cough and shortness of breath clustered as frequently co-occurring symptoms [32, 33]. In children, the next most frequent cluster consisted of systemic, enteric and mucocutaneous symptoms [32]; for adults, other clusters consisted of non-specific viral symptoms, gastrointestinal symptoms, upper respiratory symptoms, neurological symptoms, and symptoms of bronchospasm [33]. These data were included in this
global dataset so the results of these analyses are not independent of our results.

The differences in symptoms by sex were statistically significant but generally of small magnitude. Adjusted for sex and country, the common symptoms of fever, cough and shortness of breath were more common in male patients, whereas all other symptoms were equal or more common in female patients. A cohort of non-hospitalized patients with Covid-19 in Poland found greater differences in symptoms of lack of appetite (55% of women, 36% of men) and taste disorder (53% women, 40% men) [34].

Our results suggest considerable heterogeneity among countries. We have not attempted to elicit reasons for heterogeneity, which may include differences in how patients present to hospital, how they describe their symptoms, and hospitals’ criteria for admission and testing. It might also reflect differential recruitment to the study, as sites in some countries were unable to recruit confused patients due to requirements for consent, whereas in other countries the requirement for consent had been waived or assent could be obtained from a proxy. An international review of reported Covid-19 symptoms [14] found substantial variation. We explored the effect of this heterogeneity in the regression models using country as a random effect, and by repeating the analysis excluding the largest country. Each suggested an underlying pattern of lower frequencies of typical symptoms in children and older adults. Therefore, although the prevalence of each symptom reported in this study may not generalize to all settings, we have evidence to support the need to be alert to age-dependent differences across countries.

The size of this cohort is a strength. However, more than 80% of patients were recruited in a single country, and less than 1% of patients were recruited from lower-middle or low-income countries. The cohort also represents older age groups better than young ones, with only 1.8% of the cohort aged 18 years or younger. Combined with the known heterogeneity between countries, this limits the generalizability of estimates of symptom prevalence. More broadly, there is a shortage of information to guide practice outside high-income countries: a recent scoping review of clinical characteristics of Covid-19 identified no large cohorts in non-high-income countries except...
This analysis included only patients who were admitted to hospital and tested for SARS-CoV-2. This patient population is more likely to be severely unwell and more likely to exhibit symptoms typically associated with Covid-19 than people who are being managed in the community or whose disease has not been recognised. This might suggest that the reporting of ‘typical’ Covid-19 symptoms in this cohort is likely to be an overestimate of the population prevalence. Symptoms associated with less severe disease might be underestimated in this cohort. Symptoms are subjective and cannot be externally verified. Some differences for children may reflect that symptoms could only be recorded if a caregiver recognised the symptom or the child had the appropriate vocabulary to describe it. Similarly, some symptoms may be under-reported in elderly patients if there are difficulties in communication, for example due to delirium.

The absence of a control group of patients without Covid-19 in this dataset prevented estimation of specificity or positive and negative predictive values. This prevents us from advocating changes to clinical case definitions, as such decisions inevitably require a balance of false-positive and false-negative rates.

Our results suggest that reliance on clinical case definitions may result in missing cases of Covid-19, especially among children and older adults. While healthcare professionals assessing patients can make a broader assessment of a patient’s condition, non-healthcare professionals making decisions regarding isolation or exclusion from activities may adhere to the criteria more strictly. Reported prevalence of Covid-19 may also rely on strict interpretation of case definitions. In settings where comprehensive contact tracing is planned, or there is easy access to microbiological testing, a highly sensitive case definition is desirable. However, where decisions are based on clinical diagnoses, it is important to recognise other pathogens that can cause similar constellations of symptoms. This is particularly important if a treatment could be offered for an alternative diagnosis, such as influenza. Addition of symptoms such as confusion or gastrointestinal symptoms to the Covid-19 case definition could increase sensitivity, but at a cost of reduced specificity. Changes in
the senses of taste and smell have recently been added to case definitions. Our data suggest that
these criteria would detect only a small proportion of patients admitted to hospital with Covid-19
who were not included by other definitions.

These results highlight the need to consider Covid-19 even if individuals do not display
typical symptoms of the disease. This is especially the case in children and older adults. Given that
our results are likely to overestimate the sensitivity of the clinical criteria currently used to identify
patients for SARS-CoV-2 testing, our results suggest a lower limit to the proportion of people in the
community with Covid-19 who would not be identified. Addition of confusion as a symptom would
increase the sensitivity of case definitions for older adults; and inclusion of nausea and vomiting or
abdominal pain would increase sensitivity for children and young adults. The high proportion of
asymptomatic patients identified in patients aged 10 to 30 years, in spite of this cohort not being
eligible for hospital admission in many countries, suggests that universal screening in these ages
could be beneficial when there is widespread community circulation of Covid-19. Ongoing data
collection outside high-income countries is needed to establish whether alternative case definitions
are needed in different settings. Work is also ongoing to determine whether some constellations of
symptoms are associated with better or poorer outcomes than others.

ISARIC Clinical Characterisation Group

Sheryl Ann Abdukahil, Ryuzo Abe, Laurent Abel, Lara Absil, Andrew Acker, Shingo Adachi, Elisabeth
Adam, Diana Adrião, Kate Ainscough, Ali Ait Hssain, Younes Ait Tamlihat, Takako Akimoto, Tala Al-
Dabbous, Abdulrahman Al-Fares, Eman Al Qasim, Razi Alalqam, Beatrice Alex, Kévin Alexandre, Huda
Alfoudri, Kazali Enagnon Alidjnoun, Jeffrey Aliudin, Clotilde Allavena, Nathalie Allou, João Alves, Rita
Alves, Maria Amaral, Heidi Ammerlaan, Phoebe Ampaw, Roberto Andini, Claire Andrejak, Andrea
Angheben, François Angoulvant, Séverine Ansart, Massimo Antonelli, Carlos Alexandre Antunes De
Brito, Yaseen Arabi, Irene Aragao, Antonio Arcadipane, Lukas Arenz, Jean-Benoît Arlet, Christel
Arnold-Day, Lovkesh Arora, Elise Artaud-Macari, Angel Asensio, Jean Baptiste Assie, Anika Atique,
Joseph, Mark Joseph, Philippe Jouvet, Hanna Jung, Ouifiya Kafif, Florentia Kaguelidou, Sabina Kali,

Smaragdi Kalomoiri, Darshana Hewa Kandamby, Chris Kandel, Ravi Kant, Christiana Kartsonaki,

Daisuke Kasugai, Kevin Katz, Simreen Kaur Johal, Sean Keating, Andrea Kelly, Sadie Kelly, Lisa

Kennedy, Kalynn Kennon, Younes Kerroumi, Evelyne Kestelyn, Imrana Khalid, Antoine Khalil, Coralie

Khan, Irfan Khan, Michelle E Kho, Saye Khoo, Yuri Kida, Peter Kiiza, Anders Benjamin Kildal, Antoine

Kimmoun, Daisuke Kasugai, Kevin Katz, Simreen Kaur Johal, Sean Keating, Andrea Kelly, Sadie Kelly, Lisa

Kennedy, Kalynn Kennon, Younes Kerroumi, Evelyne Kestelyn, Imrana Khalid, Antoine Khalil, Coralie

Khan, Irfan Khan, Michelle E Kho, Saye Khoo, Yuri Kida, Peter Kiiza, Anders Benjamin Kildal, Antoine

Kimmoun, Detlef Kindgen-Milles, Nobuya Kitamura, Paul Kleenerman, Gry Kloumann Bekken, Stephen

Knight, Robin Kobbe, Malte Kohns Vasconcelos, Volkans Korten, Caroline Kosgei, Karolina Krawczyk,

Pavan Kumar Vecham, Deepali Kumar, Ethan Kurtzman, Demetrios Kutsogiannis, Konstantinos

Kyriakoulis, Erwan L’her, Marie Lachat, Marie Lacoste, John G Laffey, Marie Lagrange, Fabrice

Laine, Marc Lambert, François Lamontagne, Marie Langelot-Richard, Eka Yudha Lantang, Marina

Lanza, Cédric Laouénan, Samira Laribi, Delphine Lariviere, Odile Launay, Yoan Lavie-Badie, Andrew

Law, Clément Le Bihan, Cyril Le Bris, Eve Le Coustumier, Georges Le Falher, Sylvie Le Gac, Quentin Le

Hingrat, Marion Le Maréchal, Soizic Le Mestre, Vincent Le Moing, Hervé Le Nagard, Paul Le Turnier,

Rafael León, Minh Le, Marta Leal Santos, Ema Leal, James Lee, Su Hwan Lee, Todd Lee, Gary

Leeming, Bénédicte Lefebvre, Laurent Lefebvre, Benjamin Lefevre, François Lellouche, Adriën

Lemaignen, Véronique Lemee, Gretchen Lemmink, Michela Leone, Quentin Lepiller, François-Xavier

Lesquire, Olivier Lesens, Mathieu Lesouhaitier, Claire Levy-Marchal, Bruno Levy, Yves Levy, Gianluigi

Li Bassi, Janet Liang, Wei Shen Lim, Bruno Lina, Andreas Lind, Guillaume Lingas, Sylvie Lion-Daolio,

Keibun Liu, Antonio Loforte, Navy Loolong, Diogo Lopes, Dalia Lopez-Colon, Paul Loubet, Jean

Christophe Lucet, Carlos M. Luna, Olguta Lungu, Liem Luong, Dominique Luton, Ruth Lyons, Fredrik

Müller, Karl Erik Müller, Olavi Maasikas, Sarah Macdonald, Moïse Machado, Gabrielle Macheda, Juan

Macias Sanchez, Jai Madhok, Rafael Mahieu, Sophie Mahy, Lars Siegfrid Maier, Mylène Maillet,

Thomas Maitre, Maximilian Malfertheiner, Nadia Malik, Fernando Maltez, Denis Malvy, Marina

Mambert, Victoria Manda, Jose M. Mandei, Edmund Manning, Aladric Manuel, Ceila Maria Sant’Ana

Malaque, Flávio Marino, Caroline De Araújo Mariz, Charbel Maroun Eid, Ana Marques, Catherine

Marquis, Brian Marsh, Laura Marsh, John Marshall, Celina Turchi Martelli, Guillaume Martin-Blondel,
Silva, Wai Ching Sin, Vegard Skogen, Sue Smith, Benjamin Smood, Michelle Smyth, Morgane

Snacken, Dominic So, Monserrat Solis, Joshua Solomon, Tom Solomon, Emily Somers, Agnès

Sommet, Myung Jin Song, Rima Song, Tae Song, Michael Sonntagbauer, Edouard Soum, Maria Sousa

Uva, Marta Sousa, Vicente Souza-Dantas, Alexandra Sperry, Shiranee Sriskandan, Thomas

Staudinger, Stephanie-Susanne Stecher, Ymkje Stienstra, Birgitte Stiksrud, Adrian Streinu-Cercel,

Anca Streinu-Cercel, Samantha Strudwick, Ami Stuart, David Stuart, Asfia Sultana, Charlotte

Summers, Magdalena Surovcová Andrey A Svistunov, Konstantinos Syrigos, Jaques Sztajnbok,

Konstanty Szuldrzynski, François Téoulé, Shirin Tabrizi, Lysa Tagherset, Ewa Talarek, Sara Taleb,

Jelmer Talsma, Le Van Tan, Hiroyuki Tanaka, Taku Tanaka, Hayato Taniguchi, Coralie Tardivon, Pierre

Tattevin, M Azhari Taufik, Richard S. Tedder, João Teixeira, Marie-Capucine Tellier, Pleun Terpstra,

Olivier Terrier, Nicolas Terzi, Hubert Tessier-Grenier, Vincent Thibault, Simon-Djamel Thiberville,

Benoît Thill, A.A. Roger Thompson, Shaun Thompson, David Thomson, Emma C. Thomson, Duong

Bich Thuy, Ryan S. Thwaites, Peter S. Timshev, Jean-François Timsit, Bharath Kumar Tirupakuzhi

Vijayaraghavan, Maria Toki, Kristian Tonby, Rosario Maria Torres Santos-Olmo, Antoni Torres,

Margarida Torres, Théo Trioux, Huynh Trung Trieu, Cécile Tromeur, Ioannis Trontzas, Jonathan

Troost, Tiffany Trouillon, Christelle Tual, Sarah Tubiana, Helen Tuite, Lance C.W. Turtle, Pawel

Twardowski, Makoto Uchiyama, Roman Ullrich, Alberto Uribe, Asad Usman, Luís Val-Flores, Stijn Van

De Velde, Marcel Van Den Berge, Machteld Van Der Feltz, Nicky Van Der Vekens, Peter Van Der

Voort, Sylvie Van Der Werf, Marlice Van Dyk, Laura Van Gulik, Jarne Van Hattem, Steven Van

Lelyveld, Carolien Van Netten, Noémie Vanel, Henk Vanoverschelde, Charline Vauchy, Aurélie

Veislinger, Jorge Velazco, Sara Ventura, Annelies Verbon, César Vieira, Joy Ann Villanueva, Judit

Villar, Pierre-Marc Villeneuve, Andrea Villoldo, Nguyen Van Vinh Chau, Benoit Visseaux, Hannah

Visser, Aapeli Vuorinen, Fanny Vuotto, Chih-Hsien Wang, Jia Wei, Katharina Weil, Sanne Wesselius,

Murray Wham, Bryan Whelan, Nicole White, Aurélie Wiedemann, Keith Wille, Evert-Jan Wils, Ioannis

Xynogalas, Jacky Y Suen, Sophie Yacoub, Masaki Yamazaki, Yazdan Yazdanpanah, Cécile Yelnik,

Stephanie Yerkovich, Toshiki Yokoyama, Hodane Yonis, Paul Young, Saptadi Yuliarto, Marion Zabbe,

(Author contributions are listed in the supplementary material.)

Funding

This work was supported by the Department for International Development and Wellcome Trust [215091/Z/18/Z]; the Bill and Melinda Gates Foundation [OPP1209135]. Country-specific support was provided by the Canadian Institutes of Health Research Coronavirus Rapid Research Funding Opportunity [OV2170359]; the Health Research Board Ireland [CTN Award 2014-012]; National Institute for Health Research (NIHR) [award CO-CIN-01]; the Medical Research Council (MRC) [grant MC_PC_19059]; the NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine and the University of Oxford [award 200907]; NIHR HPRU in Respiratory Infections at Imperial College London with PHE [award 200927]; Liverpool Experimental Cancer Medicine Centre [grant reference C18616/A25153]; NIHR Biomedical Research Centre at Imperial College London [IS-BRC-1215-20013]; EU Platform for European Preparedness Against (Re-)emerging Epidemics (PREPARE) [FP7 project 602525]; National Institutes of Health (NIH) [UL1TR002240]; and NIHR Clinical Research Network infrastructure support. We acknowledge the generous support of all ISARIC Partners who have contributed data and expertise to this analysis, with or without dedicated funding. The views expressed are those of the authors and not necessarily those of the funders or institutions listed above.

Conflicts of Interest

M. Cheng declares grants from McGill Interdisciplinary Initiative in Infection and Immunity, and Canadian Institutes of Health Research; and personal fees from GEn1E Lifesciences (as a member of...
the scientific advisory board) and nplex biosciences (as a member of the scientific advisory board);

M. Cummings and M. O’Donnell participated as investigators for completed and ongoing clinical trials evaluating the efficacy and safety of remdesivir (sponsored by Gilead Sciences) and convalescent plasma (sponsored by Amazon), in hospitalized patients with Covid-19 – support for this work is paid to Columbia University; J. C. Holter declared grants from Research Council of Norway [grant 312780], and Vivaldi Invest A/S owned by Jon Stephenson von Tetzchner, during the conduct of the study; A.Kimmoun declared personal fees (payment for lectures) from Baxter, Aguettant, Aspen; D. Kumar declared grants and personal fees from Roche, GSK and Merck, and personal fees from Pfizer and Sanofi; F.X. Lescure declared personal fees (payment for lectures) from Gilead, MSD; and travel/accommodation/meeting expenses from Astellas, Eumedica, MSD;bA. Pesenti declared personal fees from Maquet, Novalung/Xenios, Baxter, and Boehringer Ingelheim; R.Tedder reports grants from MRC/UKRI during the conduct of the study, and has a patent United Kingdom Patent Application No. 2014047.1 “SARS-CoV-2 antibody detection assay” issued; J. Troost declared personal fees from General Electric and Procter and Gamble.

Acknowledgements

We are extremely grateful to the frontline clinical and research staff and volunteers, who collected this data in challenging circumstances, and the generosity of the patients and their families for their individual contributions in these difficult times. This work uses data provided by patients and collected by the health institutions and authorities in each country. In the UK, this study involves the National Health Service as part of their care and support #DataSavesLives. We also acknowledge the support of Jeremy J Farrar, Nahoko Shindo, Devika Dixit, Nipunie Rajapakse, Andrew Davison, David Barr, Lyndsey Castle, Martha Buckley, Debbie Malden, Katherine Newell, Kwame O’Neill, Emmanuelle Denis, Claire Petersen, Scott Mullaney, Sue MacFarlane, Nicole Maziere, Julien Martinez, Oslem Dincarslan, Annette Lake and the Irish Critical Care Trials Group. We appreciate the strong collaboration of the WHO Clinical Data Platform Team, including Silvia Bertagnolio, Soe Soe
Thwin, and Janet Diaz.

References


### Table 1. Patient demographics

<table>
<thead>
<tr>
<th>Variable</th>
<th>Overall n = 60,161</th>
<th>Female n = 25,487</th>
<th>Male n = 34,674</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years): median [IQR]</td>
<td>70 [54, 82]</td>
<td>72 [55, 83]</td>
<td>68 [54, 80]</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Age bands (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–10</td>
<td>514 (0.9)</td>
<td>221 (0.9)</td>
<td>293 (0.8)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>10–20</td>
<td>523 (0.9)</td>
<td>221 (0.9)</td>
<td>302 (0.9)</td>
<td></td>
</tr>
<tr>
<td>20–30</td>
<td>1973 (3.3)</td>
<td>873 (3.4)</td>
<td>1100 (3.2)</td>
<td></td>
</tr>
<tr>
<td>30–40</td>
<td>3211 (5.3)</td>
<td>1452 (5.7)</td>
<td>1759 (5.1)</td>
<td></td>
</tr>
<tr>
<td>40–50</td>
<td>5018 (8.3)</td>
<td>1967 (7.7)</td>
<td>3051 (8.8)</td>
<td></td>
</tr>
<tr>
<td>50–60</td>
<td>8584 (14.3)</td>
<td>3280 (12.9)</td>
<td>5304 (15.3)</td>
<td></td>
</tr>
<tr>
<td>60–70</td>
<td>9882 (16.4)</td>
<td>3702 (14.5)</td>
<td>6180 (17.8)</td>
<td></td>
</tr>
<tr>
<td>70–80</td>
<td>12351 (20.5)</td>
<td>4924 (19.3)</td>
<td>7427 (21.4)</td>
<td></td>
</tr>
<tr>
<td>80–90</td>
<td>13495 (22.4)</td>
<td>6202 (24.3)</td>
<td>7293 (21.0)</td>
<td></td>
</tr>
<tr>
<td>&gt;=90</td>
<td>4610 (7.7)</td>
<td>2645 (10.4)</td>
<td>1965 (5.7)</td>
<td></td>
</tr>
<tr>
<td>Region</td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>East Asia &amp; Pacific</td>
<td>3252 (5.4)</td>
<td>1117 (4.4)</td>
<td>2135 (6.2)</td>
<td></td>
</tr>
<tr>
<td>Europe &amp; Central Asia</td>
<td>55453 (92.2)</td>
<td>23768 (93.3)</td>
<td>31685 (91.4)</td>
<td></td>
</tr>
<tr>
<td>Latin America &amp; Caribbean</td>
<td>162 (0.3)</td>
<td>67 (0.3)</td>
<td>95 (0.3)</td>
<td></td>
</tr>
<tr>
<td>Middle East &amp; North Africa</td>
<td>91 (0.2)</td>
<td>35 (0.1)</td>
<td>56 (0.2)</td>
<td></td>
</tr>
<tr>
<td>North America</td>
<td>926 (1.5)</td>
<td>413 (1.6)</td>
<td>513 (1.5)</td>
<td></td>
</tr>
<tr>
<td>South Asia</td>
<td>267 (0.4)</td>
<td>83 (0.3)</td>
<td>184 (0.5)</td>
<td></td>
</tr>
<tr>
<td>Sub-Saharan Africa</td>
<td>10 (0.0)</td>
<td>4 (0.0)</td>
<td>6 (0.0)</td>
<td></td>
</tr>
<tr>
<td>Country income classification†</td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>High income</td>
<td>54888 (91.2)</td>
<td>23439 (92.0)</td>
<td>31449 (90.7)</td>
<td></td>
</tr>
<tr>
<td>Upper middle income</td>
<td>5003 (8.3)</td>
<td>1964 (7.7)</td>
<td>3039 (8.8)</td>
<td></td>
</tr>
<tr>
<td>Lower middle or low income</td>
<td>270 (0.4)</td>
<td>84 (0.3)</td>
<td>186 (0.5)</td>
<td></td>
</tr>
</tbody>
</table>

IQR, interquartile range

* Data are number (percent within columns) unless specified otherwise
† According to World Bank classification [35]
**Table 2. Symptoms at presentation to hospital with Covid-19**

<table>
<thead>
<tr>
<th>Variable*</th>
<th>Overall n = 60 161</th>
<th>Female n = 25 487</th>
<th>Male n = 34 674</th>
<th>P-value</th>
<th>Missing data†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever</td>
<td>41109 (68.4)</td>
<td>16663 (65.4)</td>
<td>24446 (70.5)</td>
<td>&lt;0.001</td>
<td>34 (0.1)</td>
</tr>
<tr>
<td>Cough</td>
<td>40930 (68.1)</td>
<td>16696 (65.6)</td>
<td>24234 (69.9)</td>
<td>&lt;0.001</td>
<td>50 (0.1)</td>
</tr>
<tr>
<td>Shortness of breath</td>
<td>37577 (62.5)</td>
<td>15450 (60.7)</td>
<td>22127 (63.9)</td>
<td>&lt;0.001</td>
<td>78 (0.1)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>23319 (38.8)</td>
<td>9889 (38.9)</td>
<td>13430 (38.8)</td>
<td>0.903</td>
<td>120 (0.2)</td>
</tr>
<tr>
<td>Confusion</td>
<td>13732 (24.1)</td>
<td>6108 (25.1)</td>
<td>7624 (23.4)</td>
<td>&lt;0.001</td>
<td>3196 (5.3)</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>10061 (16.8)</td>
<td>4565 (17.9)</td>
<td>5496 (15.9)</td>
<td>&lt;0.001</td>
<td>114 (0.2)</td>
</tr>
<tr>
<td>Nausea and vomiting</td>
<td>9891 (16.5)</td>
<td>5099 (20.0)</td>
<td>4792 (13.8)</td>
<td>&lt;0.001</td>
<td>110 (0.2)</td>
</tr>
<tr>
<td>Muscle pains</td>
<td>9472 (15.8)</td>
<td>3952 (15.5)</td>
<td>5520 (16.0)</td>
<td>0.167</td>
<td>124 (0.2)</td>
</tr>
<tr>
<td>Anorexia</td>
<td>613 (13.3)</td>
<td>243 (12.2)</td>
<td>370 (14.1)</td>
<td>0.065</td>
<td>55552 (92.3)</td>
</tr>
<tr>
<td>Chest pain</td>
<td>6953 (11.6)</td>
<td>3084 (12.1)</td>
<td>3869 (11.2)</td>
<td>&lt;0.001</td>
<td>118 (0.2)</td>
</tr>
<tr>
<td>Headache</td>
<td>6154 (10.3)</td>
<td>2830 (11.1)</td>
<td>3324 (9.6)</td>
<td>&lt;0.001</td>
<td>136 (0.2)</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>5305 (8.8)</td>
<td>2597 (10.2)</td>
<td>2708 (7.8)</td>
<td>&lt;0.001</td>
<td>123 (0.2)</td>
</tr>
<tr>
<td>Sore throat</td>
<td>4880 (8.1)</td>
<td>2135 (8.4)</td>
<td>2745 (8.0)</td>
<td>0.046</td>
<td>243 (0.4)</td>
</tr>
<tr>
<td>Severe dehydration</td>
<td>3451 (7.2)</td>
<td>1562 (7.6)</td>
<td>1889 (6.9)</td>
<td>0.005</td>
<td>12166 (20.2)</td>
</tr>
<tr>
<td>Wheeze</td>
<td>3845 (6.4)</td>
<td>1790 (7.0)</td>
<td>2055 (6.0)</td>
<td>&lt;0.001</td>
<td>246 (0.4)</td>
</tr>
<tr>
<td>Joint pains</td>
<td>3229 (5.4)</td>
<td>1459 (5.7)</td>
<td>1770 (5.1)</td>
<td>0.001</td>
<td>141 (0.2)</td>
</tr>
<tr>
<td>Altered sense of taste</td>
<td>2011 (5.2)</td>
<td>924 (5.5)</td>
<td>1087 (5.0)</td>
<td>0.14</td>
<td>21598 (35.9)</td>
</tr>
<tr>
<td>Altered sense of smell</td>
<td>1733 (4.5)</td>
<td>819 (4.9)</td>
<td>914 (4.2)</td>
<td>0.001</td>
<td>21483 (35.7)</td>
</tr>
<tr>
<td>Unable to walk</td>
<td>220 (4.4)</td>
<td>83 (3.8)</td>
<td>137 (4.7)</td>
<td>0.145</td>
<td>55106 (91.6)</td>
</tr>
<tr>
<td>Rhinorrhoea</td>
<td>2382 (4.0)</td>
<td>1041 (4.1)</td>
<td>1341 (3.9)</td>
<td>0.193</td>
<td>244 (0.4)</td>
</tr>
<tr>
<td>Skin ulcer</td>
<td>978 (1.9)</td>
<td>489 (2.2)</td>
<td>489 (1.6)</td>
<td>&lt;0.001</td>
<td>7924 (13.2)</td>
</tr>
<tr>
<td>Haemorrhage</td>
<td>993 (1.7)</td>
<td>429 (1.7)</td>
<td>564 (1.6)</td>
<td>0.625</td>
<td>249 (0.4)</td>
</tr>
<tr>
<td>Seizure</td>
<td>775 (1.4)</td>
<td>352 (1.4)</td>
<td>423 (1.3)</td>
<td>0.147</td>
<td>3221 (5.4)</td>
</tr>
<tr>
<td>Lower chest wall indrawing</td>
<td>688 (1.2)</td>
<td>235 (1.0)</td>
<td>453 (1.4)</td>
<td>&lt;0.001</td>
<td>3349 (5.6)</td>
</tr>
<tr>
<td>Rash</td>
<td>694 (1.2)</td>
<td>287 (1.1)</td>
<td>407 (1.2)</td>
<td>0.612</td>
<td>130 (0.2)</td>
</tr>
<tr>
<td>Lymphadenopathy</td>
<td>307 (0.5)</td>
<td>147 (0.6)</td>
<td>160 (0.5)</td>
<td>0.081</td>
<td>3340 (5.6)</td>
</tr>
<tr>
<td>Conjunctivitis</td>
<td>251 (0.4)</td>
<td>111 (0.4)</td>
<td>140 (0.4)</td>
<td>0.599</td>
<td>252 (0.4)</td>
</tr>
<tr>
<td>Ear pain</td>
<td>201 (0.4)</td>
<td>107 (0.5)</td>
<td>94 (0.3)</td>
<td>0.002</td>
<td>5275 (8.8)</td>
</tr>
</tbody>
</table>

**Composite categories**

| Fever plus one of cough or shortness of breath | 35394 (59.1) | 14174 (55.9) | 21220 (61.5) | <0.001 |
| Fever plus one of cough, rhinorrhoea, shortness of breath, sore throat, wheeze | 36006 (60.2) | 14466 (57.0) | 21540 (62.5) | <0.001 |
| Cough or fever | 50985 (85.2) | 21033 (82.9) | 29952 (86.9) | <0.001 |
| One or more of cough, shortness of breath, fever, muscle pain, sore throat | 55198 (92.2) | 22982 (90.6) | 32216 (93.4) | <0.001 |

* Data are number (percent of patients with non-missing data within columns) unless specified otherwise
† Number (percent of all patients)
‡ Patients missing any symptom included in these criteria are omitted from the composite categories
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Confusion</td>
<td>2158 (48.8)</td>
<td>5</td>
<td>3</td>
<td>7</td>
<td>11</td>
<td>26</td>
<td>62</td>
<td>178</td>
<td>528</td>
<td>897</td>
<td>441</td>
<td>230 (4.9)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>1186 (25.5)</td>
<td>10</td>
<td>6</td>
<td>18</td>
<td>24</td>
<td>29</td>
<td>79</td>
<td>137</td>
<td>276</td>
<td>452</td>
<td>155</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Nausea and vomiting</td>
<td>1040 (22.4)</td>
<td>17</td>
<td>22</td>
<td>42</td>
<td>64</td>
<td>76</td>
<td>99</td>
<td>131</td>
<td>216</td>
<td>270</td>
<td>103</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>844 (18.2)</td>
<td>6</td>
<td>21</td>
<td>49</td>
<td>71</td>
<td>54</td>
<td>87</td>
<td>117</td>
<td>173</td>
<td>195</td>
<td>71</td>
<td>1 (0.0)</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>631 (13.6)</td>
<td>7</td>
<td>6</td>
<td>22</td>
<td>21</td>
<td>29</td>
<td>49</td>
<td>97</td>
<td>148</td>
<td>216</td>
<td>65</td>
<td>1 (0.0)</td>
</tr>
<tr>
<td>Severe dehydration</td>
<td>521 (12.7)</td>
<td>3</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>6</td>
<td>9</td>
<td>26</td>
<td>121</td>
<td>225</td>
<td>94</td>
<td>541 (11.6)</td>
</tr>
<tr>
<td>Headache</td>
<td>300 (6.5)</td>
<td>1</td>
<td>6</td>
<td>32</td>
<td>27</td>
<td>32</td>
<td>24</td>
<td>45</td>
<td>53</td>
<td>54</td>
<td>26</td>
<td>2 (0.0)</td>
</tr>
<tr>
<td>Chest pain</td>
<td>295 (6.3)</td>
<td>0</td>
<td>0</td>
<td>32</td>
<td>27</td>
<td>19</td>
<td>49</td>
<td>49</td>
<td>46</td>
<td>83</td>
<td>30</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Haemorrhage</td>
<td>259 (5.6)</td>
<td>0</td>
<td>1</td>
<td>6</td>
<td>11</td>
<td>14</td>
<td>15</td>
<td>25</td>
<td>48</td>
<td>95</td>
<td>44</td>
<td>1 (0.0)</td>
</tr>
<tr>
<td>Joint pain</td>
<td>197 (4.2)</td>
<td>1</td>
<td>3</td>
<td>1</td>
<td>8</td>
<td>19</td>
<td>19</td>
<td>25</td>
<td>48</td>
<td>95</td>
<td>44</td>
<td>1 (0.0)</td>
</tr>
<tr>
<td>Seizure</td>
<td>181 (4.1)</td>
<td>5</td>
<td>3</td>
<td>6</td>
<td>7</td>
<td>13</td>
<td>27</td>
<td>35</td>
<td>52</td>
<td>52</td>
<td>16</td>
<td>230 (4.9)</td>
</tr>
<tr>
<td>Skin ulcer</td>
<td>169 (4.0)</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>3</td>
<td>2</td>
<td>12</td>
<td>49</td>
<td>57</td>
<td>37</td>
<td>379 (8.2)</td>
<td></td>
</tr>
<tr>
<td>Altered sense of smell</td>
<td>118 (3.3)</td>
<td>0</td>
<td>14</td>
<td>40</td>
<td>24</td>
<td>13</td>
<td>10</td>
<td>2</td>
<td>7</td>
<td>0</td>
<td>1029 (22.1)</td>
<td></td>
</tr>
<tr>
<td>Rhinorrhoea</td>
<td>137 (2.9)</td>
<td>2</td>
<td>21</td>
<td>44</td>
<td>27</td>
<td>18</td>
<td>11</td>
<td>8</td>
<td>1</td>
<td>3</td>
<td>0</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Altered sense of taste</td>
<td>74 (2.0)</td>
<td>1</td>
<td>4</td>
<td>23</td>
<td>9</td>
<td>7</td>
<td>1</td>
<td>7</td>
<td>8</td>
<td>11</td>
<td>3</td>
<td>1029 (22.1)</td>
</tr>
<tr>
<td>Rash</td>
<td>80 (1.7)</td>
<td>6</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>5</td>
<td>6</td>
<td>13</td>
<td>18</td>
<td>17</td>
<td>8</td>
<td>2 (0.0)</td>
</tr>
<tr>
<td>Wheeze</td>
<td>62 (1.3)</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>7</td>
<td>13</td>
<td>13</td>
<td>26</td>
<td>12</td>
<td>0 (0.0)</td>
</tr>
</tbody>
</table>

* Data are number (percent of patients with non-missing data within columns). Symptoms experienced by <25 individuals are omitted.
Figure legends

Figure 1. Flow of participants in this analysis.

4C, Coronavirus Clinical Characterisation Consortium; CCC, Critical Care Consortium; ISARIC, International Severe Acute Respiratory and emerging Infection Consortium; REDCap, Research Electronic Data Capture; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2.

Figure 2. Age-specific prevalence of symptoms at hospital admission.

Figure 3. Proportions meeting clinical criteria at hospital admission stratified by 10-year age band.

Black boxes show the proportion of individuals, with error bars showing 95% confidence intervals calculated using the Clopper–Pearson method. The size of each box is inversely proportional to the variance, so larger boxes indicate greater certainty. Grey boxes with 95% confidence intervals show the proportions in the sensitivity analysis excluding patients recruited in the United Kingdom. ‘Respiratory symptom’ is any of cough, rhinorrhoea, shortness of breath, sore throat or wheeze. Patients missing a symptom included in any criteria are excluded from all four plots.

Figure 4. Odds of symptoms among patients admitted to hospital with Covid-19, stratified by age and sex.

Each plot is the result of a logistic regression with a symptom as an outcome. Fixed effects of age in ten-year bands (baseline group 50–60 years) and sex are shown in black boxes with 95% confidence intervals. The size of each square is inversely proportional to the variance of the log odds ratio, so larger boxes indicate greater certainty. Clustering by country is included as a random intercept and
heterogeneity is depicted by circles showing the median odds ratio.

Figure 5. Age- and sex-specific odds of meeting clinical definitions among patients admitted to hospital with Covid-19, stratified by age and sex.

Each plot is the result of a logistic regression with a composite group of symptoms as an outcome. Fixed effects of age in ten-year bands (baseline group 50–60 years) and sex are shown in black boxes with 95% confidence intervals. The size of each square is inversely proportional to the variance of the log odds ratio, so larger boxes indicate greater certainty. Clustering by country is included as a random intercept and heterogeneity is depicted by circles showing the median odds ratio. ‘Respiratory symptom’ is any of cough, rhinorrhoea, shortness of breath, sore throat or wheeze.

Patients missing a symptom included in any criteria are excluded from all four plots.
ISARIC Core
n = 10 732

ISARIC Rapid
n = 1950

ISARIC 4C
n = 74 941

COVID-19 CCC
n = 2130

Non-REDCap
n = 9870

All patients in dataset
n = 99 623

Included in analysis
n = 60 161
(ISARIC Core CRF, n = 6483
ISARIC Rapid CRF, n = 446
ISARIC 4C, n = 44 327
COVID-19 CCC, n = 1041
Non-REDCap, n = 4864)

Excluded
SARS-CoV-2 not confirmed, n = 24 336
Missing all symptoms, n = 1210
Missing age, n = 1231
Missing sex, n = 133
Missing country, n = 9
Admitted before onset of Covid-19, n = 5828
Asymptomatic, n = 6715